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  Current cancer diagnosis and classification relies on clinical 
and histopathological information. However, some cases bring 
diagnostic confusion due to incomplete clinical information and 
atypical histopathologic features, together with the fact that 
criteria for histopathologic information is subjective. 
  Molecular diagnosis using tumor biomarkers offers precise 
and objective tumor diagnosis. Chromosomal changes and 
genetic mutations can be used in the molecular diagnosis of 
tumors. Loss of the long arm of chromosome 14 and activating 
mutation of c-kit are objective genetic changes in gastroin-
testinal stromal tumors (1-3), and gene rearrangement of bcr/abl 
is a diagnostic marker for acute myelogenous leukemia (4). 
However, molecular diagnosis is not generally accepted because 
of the scant number of objective tumor markers. Moreover, 
most of the genetic changes are not specific enough to accu-
rately diagnose the tumors and comprehensive mutation data-
bases for the tumors have not been explored (5).
  Recently, DNA micro-array-based tumor gene expression 
profiles have been developed and used in the tumor diagnosis 
and classification. Many studies have demonstrated that a sub-
set of genes is characteristically expressed in ovarian cancers 
(6), oral cancers (7), melanomas (8), colorectal carcinomas 
(9,10) and prostate carcinomas (11,12). Molecular classifica-
tions using DNA micro-array is useful for the determination of 
primary sites in metastatic carcinomas (13) and the classifi-
cation of soft tissue sarcomas (14). Gene expression profiles by 
DNA microarray analysis show remarkable intertumoral varia-
tions in the same histologic type of tumors. These intertumoral 
variations can be used for precise molecular classifications and 
can provide opportunities for the evaluation of genetic changes. 
Gene expression profiles can successfully differentiate the type 
of leukemia (15) and the oncogenetic pathway for the T-cell 
leukemia (16). Additionally, several studies have demonstrated 
a subset of genes representing different genetic and biological 
changes in solid tumors. Hereditary breast carcinomas differed 
in germline mutation status of BRCA1 or BRCA2 (17), and 
hence, prognosis-related molecular classifications were possible 
in prostate carcinomas (12), lymphomas (18), and gastric car-
cinomas (19).
  Although DNA micro-array analysis for tumor diagnosis and 
classification is a promising diagnostic modality for the future, 
currently, there are many limitations. First of all, accurate diag-
noses of individual tumors by gene expression profile alone are 
not always possible. This may be because no reference 
databases for comprehensive gene expression for cancer has 
been explored, and no specific group of biomarkers for the 
diagnosis of specific tumors have yet been developed. Secon-
dly, the gene expression data shows remarkable variations with-
in the same tumor. This may result from different gene expres-
sion profiles in the tumors and the different peritumoral 
lymphoid or stromal reaction status. Thirdly, early tumor detec-
tion is not possible by the gene expression profile. Currently, 
cancer diagnosis with the DNA micro-array is possible only 
when large amounts and high fractions of tumor cells are 
prepared. Detection of the membrane protein fragments or 
specific mutations in circulating tumor cells from body fluids 
is more effective and a popular approach in the early detection 
of tumors. The analysis of cancer specific mRNAs from body 
fluids containing tumor cells is another promising way; how-
ever, this can be more effectively carried out by RT-PCR 
(20,21) han by DNA micro-array. In spite of these limitations, 
DNA microarray can be best used for molecular classification 
based on genetic and biological changes.
  In this month's issue, Bae et al (22). reported gene expres-
sion profiling of uterine leiomyomas. The authors analyzed the 
gene expression profiles of leiomyomas by using the cDNA 
micro-array. They compared the gene expression profile of 
leiomyomas to that of normal myometrium and found 21 up- 
regulated and 50 down-regulated genes. Interestingly, most of the 
up-regulated genes were ones known to have nucleic acid binding 
activity. This study is a good model for the evaluation of genes 
involved in multi-step carcinogenesis. The uterine myometrium is 
mostly composed of homogeneous myometrial cells, and leio-
myoma is also a homogeneous tumor originating from myometrial 
cells. Moreover, leiomyosarcoma is another homogeneous mesen-
chymal tumor originating from myometrial cells, thus eliminating 
the heterogeneous peritumoral reaction. This unusual homogeneity 
of research materials enables one to find many valuable target 
genes by expression proteomics analysis.
  It has been reported that DNA micro-array analysis can be 
a new method for the classification of soft tissue tumors (14). 
This method can further improve the method based on histolo-
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gical findings. Specific expression of target genes, such as 
KIT expression in gastrointestinal stromal tumors, was noted 
within gene sets that distinguished different soft tissue tumors. 
DNA micro-array analysis for the multi-step model of mal-
ignant transformation in soft tissue tumors, such as leio-
myomas and leimyosarcomas, will give important information 
for genes involved in malignant transformation of soft tissue 
tumors.
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